Datasets:
dheraingoud
/
medrag-x-data

Dataset card Data Studio Files
xet
 Community
1
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed
Error code:   DatasetGenerationError
Exception:    CastError
Message:      Couldn't cast
timestamp: string
session_id: string
query_num: int64
query: string
retrieved_count: int64
contradictions_count: int64
latency: struct<total: double, ner: double, retrieval: double, contradiction: double, generation: double>
  child 0, total: double
  child 1, ner: double
  child 2, retrieval: double
  child 3, contradiction: double
  child 4, generation: double
response_length: int64
chunk_index: int64
pub_date: string
text: string
pmid: string
total_sentences_in_chunk: int64
mesh_terms: list<item: string>
  child 0, item: string
category: string
study_type: string
confidence_score: double
journal: string
chunk_id: string
title: string
publication_type: list<item: string>
  child 0, item: string
confidence_factors: struct<study_type_score: double, citation_score: double, recency_score: double, sample_size_score: d (... 36 chars omitted)
  child 0, study_type_score: double
  child 1, citation_score: double
  child 2, recency_score: double
  child 3, sample_size_score: double
  child 4, journal_impact_score: double
to
{'text': Value('string'), 'pmid': Value('string'), 'title': Value('string'), 'pub_date': Value('string'), 'journal': Value('string'), 'category': Value('string'), 'publication_type': List(Value('string')), 'mesh_terms': List(Value('string')), 'chunk_index': Value('int64'), 'total_sentences_in_chunk': Value('int64'), 'chunk_id': Value('string'), 'study_type': Value('string'), 'confidence_score': Value('float64'), 'confidence_factors': {'study_type_score': Value('float64'), 'citation_score': Value('float64'), 'recency_score': Value('float64'), 'sample_size_score': Value('float64'), 'journal_impact_score': Value('float64')}}
because column names don't match
Traceback:    Traceback (most recent call last):
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1872, in _prepare_split_single
                  for key, table in generator:
                                    ^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/packaged_modules/json/json.py", line 260, in _generate_tables
                  self._cast_table(pa_table, json_field_paths=json_field_paths),
                  ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/packaged_modules/json/json.py", line 120, in _cast_table
                  pa_table = table_cast(pa_table, self.info.features.arrow_schema)
                             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2272, in table_cast
                  return cast_table_to_schema(table, schema)
                         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2218, in cast_table_to_schema
                  raise CastError(
              datasets.table.CastError: Couldn't cast
              timestamp: string
              session_id: string
              query_num: int64
              query: string
              retrieved_count: int64
              contradictions_count: int64
              latency: struct<total: double, ner: double, retrieval: double, contradiction: double, generation: double>
                child 0, total: double
                child 1, ner: double
                child 2, retrieval: double
                child 3, contradiction: double
                child 4, generation: double
              response_length: int64
              chunk_index: int64
              pub_date: string
              text: string
              pmid: string
              total_sentences_in_chunk: int64
              mesh_terms: list<item: string>
                child 0, item: string
              category: string
              study_type: string
              confidence_score: double
              journal: string
              chunk_id: string
              title: string
              publication_type: list<item: string>
                child 0, item: string
              confidence_factors: struct<study_type_score: double, citation_score: double, recency_score: double, sample_size_score: d (... 36 chars omitted)
                child 0, study_type_score: double
                child 1, citation_score: double
                child 2, recency_score: double
                child 3, sample_size_score: double
                child 4, journal_impact_score: double
              to
              {'text': Value('string'), 'pmid': Value('string'), 'title': Value('string'), 'pub_date': Value('string'), 'journal': Value('string'), 'category': Value('string'), 'publication_type': List(Value('string')), 'mesh_terms': List(Value('string')), 'chunk_index': Value('int64'), 'total_sentences_in_chunk': Value('int64'), 'chunk_id': Value('string'), 'study_type': Value('string'), 'confidence_score': Value('float64'), 'confidence_factors': {'study_type_score': Value('float64'), 'citation_score': Value('float64'), 'recency_score': Value('float64'), 'sample_size_score': Value('float64'), 'journal_impact_score': Value('float64')}}
              because column names don't match
              
              The above exception was the direct cause of the following exception:
              
              Traceback (most recent call last):
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1347, in compute_config_parquet_and_info_response
                  parquet_operations = convert_to_parquet(builder)
                                       ^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 980, in convert_to_parquet
                  builder.download_and_prepare(
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 884, in download_and_prepare
                  self._download_and_prepare(
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 947, in _download_and_prepare
                  self._prepare_split(split_generator, **prepare_split_kwargs)
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1739, in _prepare_split
                  for job_id, done, content in self._prepare_split_single(
                                               ^^^^^^^^^^^^^^^^^^^^^^^^^^^
                File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1922, in _prepare_split_single
                  raise DatasetGenerationError("An error occurred while generating the dataset") from e
              datasets.exceptions.DatasetGenerationError: An error occurred while generating the dataset

Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.

text
string
pmid
string
title
string
pub_date
string
journal
string
category
string
publication_type
list
mesh_terms
list
chunk_index
int64
total_sentences_in_chunk
int64
chunk_id
string
study_type
string
confidence_score
float64
confidence_factors
dict
AIMS: Obesity is a global health problem, associated with significant morbidity and mortality, often due to cardiovascular (CV) diseases. While bariatric surgery is increasingly performed in patients with obesity and reduces CV risk factors, its effect on CV disease is not established.
35243488
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
2022 May 21
European heart journal
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Systematic Review" ]
[ "*Atrial Fibrillation/complications/etiology", "*Bariatric Surgery/adverse effects", "*Cardiovascular Diseases/etiology", "*Heart Failure/complications", "Humans", "*Myocardial Infarction/complications/epidemiology", "Obesity/complications/epidemiology/surgery", "Prospective Studies", "Retrospective...
0
2
chunk_000000
meta-analysis
0.5649
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We conducted a systematic review and meta-analysis to evaluate the effect of bariatric surgery on CV outcomes, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline.
35243488
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
2022 May 21
European heart journal
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Systematic Review" ]
[ "*Atrial Fibrillation/complications/etiology", "*Bariatric Surgery/adverse effects", "*Cardiovascular Diseases/etiology", "*Heart Failure/complications", "Humans", "*Myocardial Infarction/complications/epidemiology", "Obesity/complications/epidemiology/surgery", "Prospective Studies", "Retrospective...
1
1
chunk_000001
meta-analysis
0.5649
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
METHODS AND RESULTS: PubMed and Embase were searched for literature until August 2021 which compared bariatric surgery patients to non-surgical controls. Outcomes of interest were all-cause and CV mortality, atrial fibrillation (AF), heart failure (HF), myocardial infarction, and stroke.
35243488
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
2022 May 21
European heart journal
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Systematic Review" ]
[ "*Atrial Fibrillation/complications/etiology", "*Bariatric Surgery/adverse effects", "*Cardiovascular Diseases/etiology", "*Heart Failure/complications", "Humans", "*Myocardial Infarction/complications/epidemiology", "Obesity/complications/epidemiology/surgery", "Prospective Studies", "Retrospective...
2
2
chunk_000002
meta-analysis
0.5649
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We included 39 studies, all prospective or retrospective cohort studies, but randomized outcome trials were not available. Bariatric surgery was associated with a beneficial effect on all-cause mortality [pooled hazard ratio (HR) of 0.55; 95% confidence interval (CI) 0.49-0.62, P < 0.001 vs. controls], and CV mortality (HR 0.59, 95% CI 0.47-0.73, P < 0.001).
35243488
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
2022 May 21
European heart journal
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Systematic Review" ]
[ "*Atrial Fibrillation/complications/etiology", "*Bariatric Surgery/adverse effects", "*Cardiovascular Diseases/etiology", "*Heart Failure/complications", "Humans", "*Myocardial Infarction/complications/epidemiology", "Obesity/complications/epidemiology/surgery", "Prospective Studies", "Retrospective...
3
2
chunk_000003
meta-analysis
0.5649
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
In addition, bariatric surgery was also associated with a reduced incidence of HF (HR 0.50, 95% CI 0.38-0.66, P < 0.001), myocardial infarction (HR 0.58, 95% CI 0.43-0.76, P < 0.001), and stroke (HR 0.64, 95% CI 0.53-0.77, P < 0.001), while its association with AF was not statistically significant (HR 0.82, 95% CI 0.64-1.06, P = 0.12).
35243488
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
2022 May 21
European heart journal
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Systematic Review" ]
[ "*Atrial Fibrillation/complications/etiology", "*Bariatric Surgery/adverse effects", "*Cardiovascular Diseases/etiology", "*Heart Failure/complications", "Humans", "*Myocardial Infarction/complications/epidemiology", "Obesity/complications/epidemiology/surgery", "Prospective Studies", "Retrospective...
4
1
chunk_000004
meta-analysis
0.5649
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
CONCLUSION: The present systematic review and meta-analysis suggests that bariatric surgery is associated with reduced all-cause and CV mortality, and lowered incidence of several CV diseases in patients with obesity.
35243488
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
2022 May 21
European heart journal
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Systematic Review" ]
[ "*Atrial Fibrillation/complications/etiology", "*Bariatric Surgery/adverse effects", "*Cardiovascular Diseases/etiology", "*Heart Failure/complications", "Humans", "*Myocardial Infarction/complications/epidemiology", "Obesity/complications/epidemiology/surgery", "Prospective Studies", "Retrospective...
5
1
chunk_000005
meta-analysis
0.5649
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Bariatric surgery should therefore be considered in these patients.
35243488
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
2022 May 21
European heart journal
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Systematic Review" ]
[ "*Atrial Fibrillation/complications/etiology", "*Bariatric Surgery/adverse effects", "*Cardiovascular Diseases/etiology", "*Heart Failure/complications", "Humans", "*Myocardial Infarction/complications/epidemiology", "Obesity/complications/epidemiology/surgery", "Prospective Studies", "Retrospective...
6
1
chunk_000006
meta-analysis
0.5649
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
BACKGROUND: Diagnosis of heart failure with preserved ejection fraction (HFpEF) is challenging in euvolemic patients with dyspnea, and no evidence-based criteria are available. We sought to develop and then validate noninvasive diagnostic criteria that could be used to estimate the likelihood that HFpEF is present among patients with unexplained dyspnea to guide further testing.
29792299
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
2018 Aug 28
Circulation
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't" ]
[ "Adult", "Age Factors", "Aged", "Antihypertensive Agents/therapeutic use", "Atrial Fibrillation/epidemiology", "Comorbidity", "*Decision Support Techniques", "Dyspnea/epidemiology", "Echocardiography", "Evidence-Based Medicine/*methods", "*Exercise Test", "Female", "Health Status", "Heart ...
0
2
chunk_000007
unknown
0.384
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
METHODS: Consecutive patients with unexplained dyspnea referred for invasive hemodynamic exercise testing were retrospectively evaluated. Diagnosis of HFpEF (case) or noncardiac dyspnea (control) was ascertained by invasive hemodynamic exercise testing.
29792299
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
2018 Aug 28
Circulation
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't" ]
[ "Adult", "Age Factors", "Aged", "Antihypertensive Agents/therapeutic use", "Atrial Fibrillation/epidemiology", "Comorbidity", "*Decision Support Techniques", "Dyspnea/epidemiology", "Echocardiography", "Evidence-Based Medicine/*methods", "*Exercise Test", "Female", "Health Status", "Heart ...
1
2
chunk_000008
unknown
0.384
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
Logistic regression was performed to evaluate the ability of clinical findings to discriminate cases from controls. A scoring system was developed and then validated in a separate test cohort. RESULTS: The derivation cohort included 414 consecutive patients (267 cases with HFpEF and 147 controls; HFpEF prevalence, 64%).
29792299
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
2018 Aug 28
Circulation
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't" ]
[ "Adult", "Age Factors", "Aged", "Antihypertensive Agents/therapeutic use", "Atrial Fibrillation/epidemiology", "Comorbidity", "*Decision Support Techniques", "Dyspnea/epidemiology", "Echocardiography", "Evidence-Based Medicine/*methods", "*Exercise Test", "Female", "Health Status", "Heart ...
2
3
chunk_000009
unknown
0.384
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
The test cohort included 100 consecutive patients (61 with HFpEF; prevalence, 61%). Obesity, atrial fibrillation, age >60 years, treatment with >/=2 antihypertensives, echocardiographic E/e' ratio >9, and echocardiographic pulmonary artery systolic pressure >35 mm Hg were selected as the final set of predictive variables.
29792299
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
2018 Aug 28
Circulation
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't" ]
[ "Adult", "Age Factors", "Aged", "Antihypertensive Agents/therapeutic use", "Atrial Fibrillation/epidemiology", "Comorbidity", "*Decision Support Techniques", "Dyspnea/epidemiology", "Echocardiography", "Evidence-Based Medicine/*methods", "*Exercise Test", "Female", "Health Status", "Heart ...
3
2
chunk_000010
unknown
0.384
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
A weighted score based on these 6 variables was used to create a composite score (H(2)FPEF score) ranging from 0 to 9. The odds of HFpEF doubled for each 1-unit score increase (odds ratio, 1.98; 95% CI, 1.74-2.30; P<0.0001), with an area under the curve of 0.841 ( P<0.0001).
29792299
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
2018 Aug 28
Circulation
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't" ]
[ "Adult", "Age Factors", "Aged", "Antihypertensive Agents/therapeutic use", "Atrial Fibrillation/epidemiology", "Comorbidity", "*Decision Support Techniques", "Dyspnea/epidemiology", "Echocardiography", "Evidence-Based Medicine/*methods", "*Exercise Test", "Female", "Health Status", "Heart ...
4
2
chunk_000011
unknown
0.384
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
The H(2)FPEF score was superior to a currently used algorithm based on expert consensus (increase in area under the curve of 0.169; 95% CI, 0.120-0.217; P<0.0001). Performance in the independent test cohort was maintained (area under the curve, 0.886; P<0.0001).
29792299
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
2018 Aug 28
Circulation
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't" ]
[ "Adult", "Age Factors", "Aged", "Antihypertensive Agents/therapeutic use", "Atrial Fibrillation/epidemiology", "Comorbidity", "*Decision Support Techniques", "Dyspnea/epidemiology", "Echocardiography", "Evidence-Based Medicine/*methods", "*Exercise Test", "Female", "Health Status", "Heart ...
5
2
chunk_000012
unknown
0.384
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
CONCLUSIONS: The H(2)FPEF score, which relies on simple clinical characteristics and echocardiography, enables discrimination of HFpEF from noncardiac causes of dyspnea and can assist in determination of the need for further diagnostic testing in the evaluation of patients with unexplained exertional dyspnea.
29792299
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
2018 Aug 28
Circulation
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't" ]
[ "Adult", "Age Factors", "Aged", "Antihypertensive Agents/therapeutic use", "Atrial Fibrillation/epidemiology", "Comorbidity", "*Decision Support Techniques", "Dyspnea/epidemiology", "Echocardiography", "Evidence-Based Medicine/*methods", "*Exercise Test", "Female", "Health Status", "Heart ...
6
1
chunk_000013
unknown
0.384
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
BACKGROUND: The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
0
2
chunk_000014
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
METHODS: We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
1
1
chunk_000015
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK).
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
2
2
chunk_000016
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to >/=170 mm Hg).
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
3
1
chunk_000017
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
4
1
chunk_000018
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
FINDINGS: Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/89 mm Hg in participants without previous cardiovascular disease (n=186 988).
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
5
2
chunk_000019
meta-analysis
0.6057
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.5711, "journal_impact_score": 0.4 }
There was substantial spread in participants' blood pressure at baseline, with 31 239 (19.8%) of participants with previous cardiovascular disease and 14 928 (8.0%) of individuals without previous cardiovascular disease having a systolic blood pressure of less than 130 mm Hg.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
6
1
chunk_000020
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The relative effects of blood pressure-lowering treatment were proportional to the intensity of systolic blood pressure reduction. After a median 4.15 years' follow-up (Q1-Q3 2.97-4.96), 42 324 participants (12.3%) had at least one major cardiovascular event.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
7
2
chunk_000021
meta-analysis
0.5954
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.5024, "journal_impact_score": 0.4 }
In participants without previous cardiovascular disease at baseline, the incidence rate for developing a major cardiovascular event per 1000 person-years was 31.9 (95% CI 31.3-32.5) in the comparator group and 25.9 (25.4-26.4) in the intervention group.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
8
1
chunk_000022
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
In participants with previous cardiovascular disease at baseline, the corresponding rates were 39.7 (95% CI 39.0-40.5) and 36.0 (95% CI 35.3-36.7), in the comparator and intervention groups, respectively.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
9
1
chunk_000023
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Hazard ratios (HR) associated with a reduction of systolic blood pressure by 5 mm Hg for a major cardiovascular event were 0.91, 95% CI 0.89-0.94 for partipants without previous cardiovascular disease and 0.89, 0.86-0.92, for those with previous cardiovascular disease.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
10
1
chunk_000024
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
In stratified analyses, there was no reliable evidence of heterogeneity of treatment effects on major cardiovascular events by baseline cardiovascular disease status or systolic blood pressure categories.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
11
1
chunk_000025
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
INTERPRETATION: In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high-normal blood pressure values.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
12
1
chunk_000026
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
These findings suggest that a fixed degree of pharmacological blood pressure lowering is similarly effective for primary and secondary prevention of major cardiovascular disease, even at blood pressure levels currently not considered for treatment.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
13
1
chunk_000027
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Physicians communicating the indication for blood pressure lowering treatment to their patients should emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
14
1
chunk_000028
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
FUNDING: British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.
33933205
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
2021 May 1
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't" ]
[ "Antihypertensive Agents/*therapeutic use", "*Blood Pressure", "Cardiovascular Diseases/drug therapy/*prevention & control", "Heart Failure/epidemiology/mortality", "Hospitalization/statistics & numerical data", "Humans", "Hypertension/drug therapy/*prevention & control", "Intention to Treat Analysis"...
15
1
chunk_000029
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The prevalence of atrial fibrillation (AF) is increasing as the population ages. AF treatment-related complications also increase markedly in older adults (defined as >/=75 years of age for this review).
35027110
Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.
2022 Jan 18
Journal of the American College of Cardiology
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "Accidental Falls/prevention & control", "Aged", "Alcohol Drinking/adverse effects", "Anti-Arrhythmia Agents/therapeutic use", "Anticoagulants/therapeutic use", "Atrial Appendage/surgery", "Atrial Fibrillation/*therapy", "Catheter Ablation", "Cognitive Dysfunction/complications", "Coronary Artery ...
0
2
chunk_000030
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The older AF population has a high risk of stroke, bleeding, and death. Syncope and fall-related injuries are the most common reasons for nonprescription of oral anticoagulation (OAC), and are more common in older adults when OACs are used with antiarrhythmic drugs.
35027110
Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.
2022 Jan 18
Journal of the American College of Cardiology
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "Accidental Falls/prevention & control", "Aged", "Alcohol Drinking/adverse effects", "Anti-Arrhythmia Agents/therapeutic use", "Anticoagulants/therapeutic use", "Atrial Appendage/surgery", "Atrial Fibrillation/*therapy", "Catheter Ablation", "Cognitive Dysfunction/complications", "Coronary Artery ...
1
2
chunk_000031
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Digoxin may be useful for rate control, but associations with increased mortality limit its use. Beyond rate and rhythm control considerations, stroke prophylaxis is critical to AF management, and the benefits of direct OACs, compared with warfarin, extend to older adults.
35027110
Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.
2022 Jan 18
Journal of the American College of Cardiology
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "Accidental Falls/prevention & control", "Aged", "Alcohol Drinking/adverse effects", "Anti-Arrhythmia Agents/therapeutic use", "Anticoagulants/therapeutic use", "Atrial Appendage/surgery", "Atrial Fibrillation/*therapy", "Catheter Ablation", "Cognitive Dysfunction/complications", "Coronary Artery ...
2
2
chunk_000032
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Invasive procedures such as AF catheter ablation, pacemaker implantation/atrioventricular junction ablation, and left atrial appendage occlusion may be useful in appropriately selected cases. However, older adults have generally been under-represented in clinical trials.
35027110
Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review.
2022 Jan 18
Journal of the American College of Cardiology
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "Accidental Falls/prevention & control", "Aged", "Alcohol Drinking/adverse effects", "Anti-Arrhythmia Agents/therapeutic use", "Anticoagulants/therapeutic use", "Atrial Appendage/surgery", "Atrial Fibrillation/*therapy", "Catheter Ablation", "Cognitive Dysfunction/complications", "Coronary Artery ...
3
2
chunk_000033
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
BACKGROUND: The risk of major adverse cardiovascular events is substantially increased following a stroke. Although exercise-based cardiac rehabilitation has been shown to improve prognosis following cardiac events, it is not part of routine care for people following a stroke.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
0
2
chunk_000034
unknown
0.3699
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We, therefore, investigated the association between cardiac rehabilitation and major adverse cardiovascular events for people following a stroke. Following a stroke, individuals have an increased risk of new-onset cardiovascular complications.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
1
2
chunk_000035
unknown
0.3699
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
However, the incidence and long-term clinical consequence of newly diagnosed cardiovascular complications following a stroke is unclear. The aim of the present study was to investigate the incidence and long-term clinical outcomes of newly diagnosed cardiovascular complications following incident ischemic stroke.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
2
2
chunk_000036
unknown
0.3699
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
METHODS: A retrospective cohort study was conducted using anonymized electronic medical records from 53 participating health care organizations. Patients with incident ischemic stroke aged >/=18 years with 5 years of follow-up were included.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
3
2
chunk_000037
cohort
0.4749
{ "study_type_score": 0.7, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Patients who were diagnosed with new-onset cardiovascular complications (heart failure, severe ventricular arrhythmia, atrial fibrillation, ischemic heart disease, Takotsubo syndrome) within 4-weeks (exposure) of incident ischemic stroke were 1:1 propensity score-matched (age, sex, ethnicity, comorbidities, cardiovascular care) with ischemic stroke patients who were not diagnosed with a new-onset cardiovascular complication (control).
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
4
1
chunk_000038
unknown
0.3699
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Logistic regression models produced odds ratios (OR) with 95% CIs for 5-year incidence of all-cause mortality, recurrent stroke, hospitalization, and acute myocardial infarction. RESULTS: Of 365 383 patients with stroke with 5-year follow-up: 11.1% developed acute coronary syndrome; 8.8% atrial fibrillation/flutter; 6.4% heart failure; 1.2% severe ventricular arrythmias; and 0.1% Takotsubo syndrome within 4 weeks of incident ischemic stroke.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
5
2
chunk_000039
rct
0.5824
{ "study_type_score": 0.9, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.5169, "journal_impact_score": 0.4 }
Following propensity score matching, odds of 5-year all-cause mortality were significantly higher in stroke patients with acute coronary syndrome (odds ratio, 1.49 [95% CI, 1.44-1.54]), atrial fibrillation/flutter (1.45 [1.40-1.50]), heart failure (1.83 [1.76-1.91]), and severe ventricular arrhythmias (2.08 [1.90-2.29]), compared with matched controls.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
6
1
chunk_000040
unknown
0.3699
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Odds of 5-year rehospitalization and acute myocardial infarction were also significantly higher for patients with stroke diagnosed with new-onset cardiovascular complications. Takotsubo syndrome was associated with significantly higher odds of 5-year composite major adverse cardiovascular events (1.89 [1.29-2.77]).
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
7
2
chunk_000041
rct
0.5349
{ "study_type_score": 0.9, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Atrial fibrillation/flutter was the only new-onset cardiac complication associated with significantly higher odds of recurrent ischemic stroke at 5 years (1.10 [1.07-1.14]). CONCLUSIONS: New-onset cardiovascular complications diagnosed following an ischemic stroke are very common and associate with significantly worse 5-year prognosis in terms of major adverse cardiovascular events.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
8
2
chunk_000042
unknown
0.3699
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
People with stroke and newly diagnosed cardiovascular complications had >50% prevalence of recurrent stroke at 5 years.
35354300
Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
2022 May
Stroke
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "*Acute Coronary Syndrome/complications/epidemiology/therapy", "Adolescent", "Adult", "*Atrial Fibrillation/complications/diagnosis/epidemiology", "*Heart Failure/complications", "Humans", "Incidence", "*Ischemic Stroke", "*Myocardial Infarction/epidemiology", "Retrospective Studies", "Risk Fact...
9
1
chunk_000043
unknown
0.3699
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Aldosterone's role in the kidney and its pathophysiologic actions in hypertension are well known. However, its role or that of its receptor [minieralocorticoid receptor (MR)] in other cardiovascular (CV) disease are less well described.
35388416
Aldosterone and cardiovascular diseases.
2023 Mar 17
Cardiovascular research
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't", "Review" ]
[ "Humans", "Aldosterone", "*Cardiovascular Diseases", "*Atrial Fibrillation/drug therapy", "Mineralocorticoid Receptor Antagonists/therapeutic use", "*Heart Failure/drug therapy", "*Hypertension/diagnosis/drug therapy", "*Myocardial Infarction/drug therapy", "*Atherosclerosis/drug therapy", "*Strok...
0
2
chunk_000044
review
0.432
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
To identify their potential roles in six CV conditions (heart failure, myocardial infarction, atrial fibrillation, stroke, atherosclerosis, and thrombosis), we assessed these associations in the following four areas: (i) mechanistic studies in rodents and humans; (ii) pre-clinical studies of MR antagonists; (iii) clinical trials of MR antagonists; and (iv) genetics.
35388416
Aldosterone and cardiovascular diseases.
2023 Mar 17
Cardiovascular research
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't", "Review" ]
[ "Humans", "Aldosterone", "*Cardiovascular Diseases", "*Atrial Fibrillation/drug therapy", "Mineralocorticoid Receptor Antagonists/therapeutic use", "*Heart Failure/drug therapy", "*Hypertension/diagnosis/drug therapy", "*Myocardial Infarction/drug therapy", "*Atherosclerosis/drug therapy", "*Strok...
1
1
chunk_000045
review
0.432
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The data were acquired from an online search of the National Library of Medicine using the PubMed search engine from January 2011 through June 2021. There were 3702 publications identified with 200 publications meeting our inclusion and exclusion criteria.
35388416
Aldosterone and cardiovascular diseases.
2023 Mar 17
Cardiovascular research
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't", "Review" ]
[ "Humans", "Aldosterone", "*Cardiovascular Diseases", "*Atrial Fibrillation/drug therapy", "Mineralocorticoid Receptor Antagonists/therapeutic use", "*Heart Failure/drug therapy", "*Hypertension/diagnosis/drug therapy", "*Myocardial Infarction/drug therapy", "*Atherosclerosis/drug therapy", "*Strok...
2
2
chunk_000046
review
0.432
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Data strongly supported an association between heart failure and dysregulated aldosterone/MR. This association is not surprising given aldosterone/MR's prominent role in regulating sodium/volume homeostasis.
35388416
Aldosterone and cardiovascular diseases.
2023 Mar 17
Cardiovascular research
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't", "Review" ]
[ "Humans", "Aldosterone", "*Cardiovascular Diseases", "*Atrial Fibrillation/drug therapy", "Mineralocorticoid Receptor Antagonists/therapeutic use", "*Heart Failure/drug therapy", "*Hypertension/diagnosis/drug therapy", "*Myocardial Infarction/drug therapy", "*Atherosclerosis/drug therapy", "*Strok...
3
2
chunk_000047
review
0.432
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Atrial fibrillation and myocardial infarction are also associated with dysregulated aldosterone/MR, but less strongly. For the most part, the data were insufficient to determine whether there was a relationship between atherosclerosis, stroke, or thrombosis and aldosterone/MR dysregulation.
35388416
Aldosterone and cardiovascular diseases.
2023 Mar 17
Cardiovascular research
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't", "Review" ]
[ "Humans", "Aldosterone", "*Cardiovascular Diseases", "*Atrial Fibrillation/drug therapy", "Mineralocorticoid Receptor Antagonists/therapeutic use", "*Heart Failure/drug therapy", "*Hypertension/diagnosis/drug therapy", "*Myocardial Infarction/drug therapy", "*Atherosclerosis/drug therapy", "*Strok...
4
2
chunk_000048
review
0.432
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
This review clearly documented an expanding role for aldosterone/MR's dysregulation in CV diseases beyond hypertension. How expansive it might be is limited by the currently available data. It is anticipated that with an increased focus on aldosterone/MR's potential roles in these diseases, additional clinical and pre-clinical data will clarify these relationships, thereby, opening approaches to use modulators of aldosterone/MR's action to more precisely treat these CV conditions.
35388416
Aldosterone and cardiovascular diseases.
2023 Mar 17
Cardiovascular research
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't", "Review" ]
[ "Humans", "Aldosterone", "*Cardiovascular Diseases", "*Atrial Fibrillation/drug therapy", "Mineralocorticoid Receptor Antagonists/therapeutic use", "*Heart Failure/drug therapy", "*Hypertension/diagnosis/drug therapy", "*Myocardial Infarction/drug therapy", "*Atherosclerosis/drug therapy", "*Strok...
5
3
chunk_000049
review
0.432
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Acute heart failure is a common and severe condition in Danish emergency hospitals. Hypertensive pulmonary oedema, cardiogenic shock and congestive heart failure are the most common phenotypes. The aim of this review is to summarise the most recent international guidelines for acute triage and treatment of acute heart failure.
33046187
[Acute heart failure].
2020 Oct 5
Ugeskrift for laeger
Cardiovascular
[ "Journal Article", "Review" ]
[ "Acute Disease", "*Heart Failure/drug therapy/therapy", "Humans", "*Hypertension/drug therapy", "*Pulmonary Edema/diagnosis/etiology/therapy", "Shock, Cardiogenic/drug therapy", "Vasodilator Agents/therapeutic use" ]
0
3
chunk_000050
review
0.3871
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.4354, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Afterload is reduced with nitrates, congestion is treated with intravenous loop-diuretics, and in selected patients, cardiac output could be increased by inotropic drugs or mechanical support devices.
33046187
[Acute heart failure].
2020 Oct 5
Ugeskrift for laeger
Cardiovascular
[ "Journal Article", "Review" ]
[ "Acute Disease", "*Heart Failure/drug therapy/therapy", "Humans", "*Hypertension/drug therapy", "*Pulmonary Edema/diagnosis/etiology/therapy", "Shock, Cardiogenic/drug therapy", "Vasodilator Agents/therapeutic use" ]
1
1
chunk_000051
review
0.3871
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.4354, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
BACKGROUND: The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain.
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
0
1
chunk_000052
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. METHODS: We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group.
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
1
2
chunk_000053
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55-64 years, 65-74 years, 75-84 years, and >/=85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to >/=170 mm Hg systolic blood pressure and from <70 mm Hg to >/=110 mm Hg diastolic).
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
2
3
chunk_000054
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission.
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
3
2
chunk_000055
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
FINDINGS: We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59-75]), with 42 960 (12.0%) participants younger than 55 years, 128 437 (35.8%) aged 55-64 years, 128 506 (35.8%) 65-74 years, 54 016 (15.1%) 75-84 years, and 4788 (1.3%) 85 years and older.
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
4
2
chunk_000056
meta-analysis
0.6055
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.57, "journal_impact_score": 0.4 }
The hazard ratios for the risk of major cardiovascular events per 5 mm Hg reduction in systolic blood pressure for each age group were 0.82 (95% CI 0.76-0.88) in individuals younger than 55 years, 0.91 (0.88-0.95) in those aged 55-64 years, 0.91 (0.88-0.95) in those aged 65-74 years, 0.91 (0.87-0.96) in those aged 75-84 years, and 0.99 (0.87-1.12) in those aged 85 years and older (adjusted p(interaction)=0.050).
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
5
1
chunk_000057
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Similar patterns of proportional risk reductions were observed for a 3 mm Hg reduction in diastolic blood pressure. Absolute risk reductions for major cardiovascular events varied by age and were larger in older groups (adjusted p(interaction)=0.024).
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
6
2
chunk_000058
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We did not find evidence for any clinically meaningful heterogeneity of relative treatment effects across different baseline blood pressure categories in any age group. INTERPRETATION: Pharmacological blood pressure reduction is effective into old age, with no evidence that relative risk reductions for prevention of major cardiovascular events vary by systolic or diastolic blood pressure levels at randomisation, down to less than 120/70 mm Hg.
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
7
2
chunk_000059
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Pharmacological blood pressure reduction should, therefore, be considered an important treatment option regardless of age, with the removal of age-related blood-pressure thresholds from international guidelines.
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
8
1
chunk_000060
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
FUNDING: British Heart Foundation, National Institute of Health Research Oxford Biomedical Research Centre, Oxford Martin School.
34461040
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
2021 Sep 18
Lancet (London, England)
Cardiovascular
[ "Journal Article", "Research Support, Non-U.S. Gov't" ]
[ "Age Factors", "Aged", "Aged, 80 and over", "Antihypertensive Agents/*therapeutic use", "Blood Pressure/*drug effects", "Cardiovascular Diseases/*prevention & control", "Female", "Heart Failure/mortality", "Hospitalization", "Humans", "Hypertension/*drug therapy", "Male", "*Meta-Analysis as ...
9
1
chunk_000061
meta-analysis
0.55
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.5001, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Chymase, a chymotrypsin-like serine protease that is abundant in secretory granules from mast cells, has been identified to be a key enzyme in the local renin-angiotensin system (RAS) that generates angiotensin II (Ang II) independent of angiotensin converting enzyme (ACE).
23176221
Chymase inhibitors.
2013
Current pharmaceutical design
Cardiovascular
[ "Journal Article", "Review" ]
[ "Acetamides/pharmacology", "Animals", "Atrial Fibrillation/drug therapy", "Azetidines/pharmacology", "Benzoates/pharmacology", "Cardiovascular Diseases/drug therapy/etiology", "Chymases/*antagonists & inhibitors/physiology", "Heart Failure/drug therapy", "Humans", "Hypertension/drug therapy", "M...
0
1
chunk_000062
review
0.333
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.165, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The pathophysiological significance of alternative Ang II-forming pathways in human cardiovascular disease remains controversial. Although chymase inhibitors, unlike ACE inhibitors and Ang II type 1 receptor blockers (ARBs), may only play a small role in the regulation of the systemic RAS, the possible applications of chymase inhibitors as new drugs that inhibit the local RAS to prevent cardiovascular diseases are described in animal models.
23176221
Chymase inhibitors.
2013
Current pharmaceutical design
Cardiovascular
[ "Journal Article", "Review" ]
[ "Acetamides/pharmacology", "Animals", "Atrial Fibrillation/drug therapy", "Azetidines/pharmacology", "Benzoates/pharmacology", "Cardiovascular Diseases/drug therapy/etiology", "Chymases/*antagonists & inhibitors/physiology", "Heart Failure/drug therapy", "Humans", "Hypertension/drug therapy", "M...
1
2
chunk_000063
review
0.333
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.165, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
In this review, we discuss the possible application of chymase inhibitors as new drugs to inhibit the RAS in mainly cardiovascular diseases.
23176221
Chymase inhibitors.
2013
Current pharmaceutical design
Cardiovascular
[ "Journal Article", "Review" ]
[ "Acetamides/pharmacology", "Animals", "Atrial Fibrillation/drug therapy", "Azetidines/pharmacology", "Benzoates/pharmacology", "Cardiovascular Diseases/drug therapy/etiology", "Chymases/*antagonists & inhibitors/physiology", "Heart Failure/drug therapy", "Humans", "Hypertension/drug therapy", "M...
2
1
chunk_000064
review
0.333
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.165, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The article summarizes new advances in cardiology published in 2022, which have an impact to everyday practice of not only internists and cardiologists. The administration of polypill to patients after myocardial infarction (SECURE study), early pharmacotherapy of hypertension in pregnant women with blood pressure exceeding 140/90 mmHg (CHAP study), or the administration of dapagliflozin to patients with heart failure with preserved or mildly reduced ejection fraction (DELIVER study) have been shown to be effective.
36931883
[News in cardiology].
2023 Winter
Vnitrni lekarstvi
Cardiovascular
[ "Journal Article" ]
[ "Pregnancy", "Humans", "Female", "Antihypertensive Agents/therapeutic use", "*Hypertension/drug therapy", "*Cardiology", "*Heart Failure/drug therapy", "*Myocardial Infarction", "Stroke Volume" ]
0
2
chunk_000065
rct
0.552
{ "study_type_score": 0.9, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Patients with heart failure do not have to limit their sodium intake (SODIUM-HF study), on the contrary, they benefit from up-titration of guideline-recommended drugs to the maximum tolerated doses as quickly as possible (STRONG-HF study).
36931883
[News in cardiology].
2023 Winter
Vnitrni lekarstvi
Cardiovascular
[ "Journal Article" ]
[ "Pregnancy", "Humans", "Female", "Antihypertensive Agents/therapeutic use", "*Hypertension/drug therapy", "*Cardiology", "*Heart Failure/drug therapy", "*Myocardial Infarction", "Stroke Volume" ]
1
1
chunk_000066
guideline
0.537
{ "study_type_score": 0.85, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
For antihypertensives, it does not matter whether they are taken in the morning or in the evening (TIME study), nor has there been found any difference in the incidence of cardiovascular events with hydrochlorothiazide and chlortalidone (DCP study).
36931883
[News in cardiology].
2023 Winter
Vnitrni lekarstvi
Cardiovascular
[ "Journal Article" ]
[ "Pregnancy", "Humans", "Female", "Antihypertensive Agents/therapeutic use", "*Hypertension/drug therapy", "*Cardiology", "*Heart Failure/drug therapy", "*Myocardial Infarction", "Stroke Volume" ]
2
1
chunk_000067
unknown
0.387
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
In patients with increased cardiovascular risk, highly sensitive troponin should be measured before non-cardiac surgery as well as 24 and 48 hours after surgery to detect perioperative myocardial infarction.
36931883
[News in cardiology].
2023 Winter
Vnitrni lekarstvi
Cardiovascular
[ "Journal Article" ]
[ "Pregnancy", "Humans", "Female", "Antihypertensive Agents/therapeutic use", "*Hypertension/drug therapy", "*Cardiology", "*Heart Failure/drug therapy", "*Myocardial Infarction", "Stroke Volume" ]
3
1
chunk_000068
rct
0.552
{ "study_type_score": 0.9, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Different blood pressure and oxygenation targets in patients after resuscitation for out-of-hospital cardiac arrest do not affect the outcomes of their treatment.
36931883
[News in cardiology].
2023 Winter
Vnitrni lekarstvi
Cardiovascular
[ "Journal Article" ]
[ "Pregnancy", "Humans", "Female", "Antihypertensive Agents/therapeutic use", "*Hypertension/drug therapy", "*Cardiology", "*Heart Failure/drug therapy", "*Myocardial Infarction", "Stroke Volume" ]
4
1
chunk_000069
unknown
0.387
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
AIMS: It is unclear whether the future risk of cardiovascular events in breast cancer (Bc) survivors is greater than in the general population. This meta-analysis quantifies the risk of cardiovascular disease development in Bc patients, compared to the risk in a general matched cancer-free population, and reports the incidence of cardiovascular events in patients with Bc.
37499186
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis.
2023 Dec 21
European journal of preventive cardiology
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't", "Systematic Review" ]
[ "Humans", "Female", "*Cardiovascular Diseases/diagnosis/epidemiology/complications", "*Breast Neoplasms/epidemiology/therapy", "*Stroke/diagnosis/epidemiology", "*Brain Ischemia", "*Cancer Survivors", "*Myocardial Infarction/epidemiology", "*Coronary Artery Disease/complications", "*Heart Failure"...
0
2
chunk_000070
meta-analysis
0.582
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
METHODS AND RESULTS: We searched PubMed, Scopus, and Web of Science databases (up to 23 March 2022) for observational studies and post hoc analyses of randomized controlled trials. Cardiovascular death, heart failure (HF), atrial fibrillation (AF), coronary artery disease (CAD), myocardial infarction (MI), and stroke were the individual endpoints for our meta-analysis.
37499186
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis.
2023 Dec 21
European journal of preventive cardiology
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't", "Systematic Review" ]
[ "Humans", "Female", "*Cardiovascular Diseases/diagnosis/epidemiology/complications", "*Breast Neoplasms/epidemiology/therapy", "*Stroke/diagnosis/epidemiology", "*Brain Ischemia", "*Cancer Survivors", "*Myocardial Infarction/epidemiology", "*Coronary Artery Disease/complications", "*Heart Failure"...
1
2
chunk_000071
meta-analysis
0.582
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We pooled incidence rates (IRs) and risk in hazard ratios (HRs), using random-effects meta-analyses. Heterogeneity was reported through the I2 statistic, and publication bias was examined using funnel plots and Egger's test in the meta-analysis of risk.
37499186
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis.
2023 Dec 21
European journal of preventive cardiology
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't", "Systematic Review" ]
[ "Humans", "Female", "*Cardiovascular Diseases/diagnosis/epidemiology/complications", "*Breast Neoplasms/epidemiology/therapy", "*Stroke/diagnosis/epidemiology", "*Brain Ischemia", "*Cancer Survivors", "*Myocardial Infarction/epidemiology", "*Coronary Artery Disease/complications", "*Heart Failure"...
2
2
chunk_000072
meta-analysis
0.582
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
One hundred and forty-two studies were identified in total, 26 (836 301 patients) relevant to the relative risk and 116 (2 111 882 patients) relevant to IRs. Compared to matched cancer-free controls, Bc patients had higher risk for cardiovascular death within 5 years of cancer diagnosis [HR = 1.09; 95% confidence interval (CI): 1.07, 1.11], HF within 10 years (HR = 1.21; 95% CI: 1.1, 1.33), and AF within 3 years (HR = 1.13; 95% CI: 1.05, 1.21).
37499186
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis.
2023 Dec 21
European journal of preventive cardiology
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't", "Systematic Review" ]
[ "Humans", "Female", "*Cardiovascular Diseases/diagnosis/epidemiology/complications", "*Breast Neoplasms/epidemiology/therapy", "*Stroke/diagnosis/epidemiology", "*Brain Ischemia", "*Cancer Survivors", "*Myocardial Infarction/epidemiology", "*Coronary Artery Disease/complications", "*Heart Failure"...
3
2
chunk_000073
meta-analysis
0.6403
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.5892, "journal_impact_score": 0.4 }
The pooled IR for cardiovascular death was 1.73 (95% CI 1.18, 2.53), 4.44 (95% CI 3.33, 5.92) for HF, 4.29 (95% CI 3.09, 5.94) for CAD, 1.98 (95% CI 1.24, 3.16) for MI, 4.33 (95% CI 2.97, 6.30) for stroke of any type, and 2.64 (95% CI 2.97, 6.30) for ischaemic stroke.
37499186
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis.
2023 Dec 21
European journal of preventive cardiology
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't", "Systematic Review" ]
[ "Humans", "Female", "*Cardiovascular Diseases/diagnosis/epidemiology/complications", "*Breast Neoplasms/epidemiology/therapy", "*Stroke/diagnosis/epidemiology", "*Brain Ischemia", "*Cancer Survivors", "*Myocardial Infarction/epidemiology", "*Coronary Artery Disease/complications", "*Heart Failure"...
4
1
chunk_000074
meta-analysis
0.582
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
CONCLUSION: Breast cancer exposure was associated with the increased risk for cardiovascular death, HF, and AF. The pooled incidence for cardiovascular endpoints varied depending on population characteristics and endpoint studied.
37499186
Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis.
2023 Dec 21
European journal of preventive cardiology
Cardiovascular
[ "Journal Article", "Meta-Analysis", "Research Support, Non-U.S. Gov't", "Systematic Review" ]
[ "Humans", "Female", "*Cardiovascular Diseases/diagnosis/epidemiology/complications", "*Breast Neoplasms/epidemiology/therapy", "*Stroke/diagnosis/epidemiology", "*Brain Ischemia", "*Cancer Survivors", "*Myocardial Infarction/epidemiology", "*Coronary Artery Disease/complications", "*Heart Failure"...
5
2
chunk_000075
meta-analysis
0.582
{ "study_type_score": 1, "citation_score": 0.3, "recency_score": 0.6598, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Although most cases of sustained atrial fibrillation are associated with mitral valve disease, hypertension, cardiac failure and atherosclerotic heart disease, some cases occur in the absence of any identifiable organic pathology.
6211071
Atrial fibrillation.
1982 Jun
American family physician
Cardiovascular
[ "Journal Article" ]
[ "Age Factors", "Aged", "Atrial Fibrillation/diagnosis/etiology/*therapy", "Cardiomegaly/complications", "Digoxin/therapeutic use", "Electric Countershock", "Electrocardiography", "Heart Failure/complications", "Humans", "Hypertension/complications", "Male", "Middle Aged", "Mitral Valve Steno...
0
1
chunk_000076
unknown
0.2554
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.0022, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The consequences of atrial fibrillation include reduction in cardiac output, systemic emboli and an exaggerated ventricular response to exercise. In most clinical situations, digoxin is the drug of choice for controlling the ventricular response.
6211071
Atrial fibrillation.
1982 Jun
American family physician
Cardiovascular
[ "Journal Article" ]
[ "Age Factors", "Aged", "Atrial Fibrillation/diagnosis/etiology/*therapy", "Cardiomegaly/complications", "Digoxin/therapeutic use", "Electric Countershock", "Electrocardiography", "Heart Failure/complications", "Humans", "Hypertension/complications", "Male", "Middle Aged", "Mitral Valve Steno...
1
2
chunk_000077
unknown
0.2554
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.0022, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Cardioversion should be undertaken in appropriately selected patients.
6211071
Atrial fibrillation.
1982 Jun
American family physician
Cardiovascular
[ "Journal Article" ]
[ "Age Factors", "Aged", "Atrial Fibrillation/diagnosis/etiology/*therapy", "Cardiomegaly/complications", "Digoxin/therapeutic use", "Electric Countershock", "Electrocardiography", "Heart Failure/complications", "Humans", "Hypertension/complications", "Male", "Middle Aged", "Mitral Valve Steno...
2
1
chunk_000078
unknown
0.2554
{ "study_type_score": 0.35, "citation_score": 0.3, "recency_score": 0.0022, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Sleep-disordered breathing (SDB) is a highly prevalent chronic disease in older adults. A growing body of evidence demonstrates that SDB in older adults is linked to many adverse cardiovascular, neurocognitive, and metabolic sequelae.
29412981
Apnea in Older Adults.
2018 Mar
Sleep medicine clinics
Cardiovascular
[ "Journal Article", "Review" ]
[ "Accidents, Traffic/*statistics & numerical data", "Aged", "Atrial Fibrillation/epidemiology", "Cardiovascular Diseases/*epidemiology", "Cognitive Dysfunction/*epidemiology", "Continuous Positive Airway Pressure", "Diabetes Mellitus, Type 2/*epidemiology", "Heart Failure/epidemiology", "Humans", "...
0
2
chunk_000079
review
0.366
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
However, several unanswered questions remain regarding the diagnosis, consequences, and treatment of SDB in older adults. This review presents the current evidence pertaining to the management of SDB in older adults and identifies crucial gaps in knowledge that need further investigation.
29412981
Apnea in Older Adults.
2018 Mar
Sleep medicine clinics
Cardiovascular
[ "Journal Article", "Review" ]
[ "Accidents, Traffic/*statistics & numerical data", "Aged", "Atrial Fibrillation/epidemiology", "Cardiovascular Diseases/*epidemiology", "Cognitive Dysfunction/*epidemiology", "Continuous Positive Airway Pressure", "Diabetes Mellitus, Type 2/*epidemiology", "Heart Failure/epidemiology", "Humans", "...
1
2
chunk_000080
review
0.366
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.33, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The management of hypertension in the elderly, particularly concerning atherosclerotic cardiovascular disease (ASCVD) and comorbidities, is crucial given its prevalence and impact on morbidity and mortality.
40410113
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.
2025 Jul
Journal of the Formosan Medical Association = Taiwan yi zhi
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "*Hypertension/drug therapy/complications", "Aged", "*Atrial Fibrillation/drug therapy", "*Heart Failure/drug therapy", "*Antihypertensive Agents/therapeutic use", "*Atherosclerosis/drug therapy", "Blood Pressure/drug effects", "*Aortic Valve Stenosis/drug therapy", "Practice Guidelines ...
0
1
chunk_000081
review
0.4741
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
It is important to individualize pharmacotherapy in elderly patients, including basing the dose on age-related changes in organ function and drug pharmacokinetics. In elderly patients with hypertension and ASCVD, despite slight differences among guideline recommendations, the emphasis is on achieving a systolic blood pressure (BP) < 130 mmHg.
40410113
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.
2025 Jul
Journal of the Formosan Medical Association = Taiwan yi zhi
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "*Hypertension/drug therapy/complications", "Aged", "*Atrial Fibrillation/drug therapy", "*Heart Failure/drug therapy", "*Antihypertensive Agents/therapeutic use", "*Atherosclerosis/drug therapy", "Blood Pressure/drug effects", "*Aortic Valve Stenosis/drug therapy", "Practice Guidelines ...
1
2
chunk_000082
review
0.4741
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
The optimal target for patients with atrial fibrillation remains under debate, with suggestions ranging from <130/80 mmHg to <140/90 mmHg. The role of anticoagulation treatment further complicates BP management in these patients.
40410113
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.
2025 Jul
Journal of the Formosan Medical Association = Taiwan yi zhi
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "*Hypertension/drug therapy/complications", "Aged", "*Atrial Fibrillation/drug therapy", "*Heart Failure/drug therapy", "*Antihypertensive Agents/therapeutic use", "*Atherosclerosis/drug therapy", "Blood Pressure/drug effects", "*Aortic Valve Stenosis/drug therapy", "Practice Guidelines ...
2
2
chunk_000083
review
0.4741
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
BP targets also differ among guidelines regarding heart failure in the elderly, although maintaining systolic BP < 140/90 mmHg is generally advocated. In hypertensive elderly patients with aortic stenosis, the optimal BP targets are even less clear, and should consider the risks of adverse outcomes.
40410113
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.
2025 Jul
Journal of the Formosan Medical Association = Taiwan yi zhi
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "*Hypertension/drug therapy/complications", "Aged", "*Atrial Fibrillation/drug therapy", "*Heart Failure/drug therapy", "*Antihypertensive Agents/therapeutic use", "*Atherosclerosis/drug therapy", "Blood Pressure/drug effects", "*Aortic Valve Stenosis/drug therapy", "Practice Guidelines ...
3
2
chunk_000084
review
0.4741
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Overall, individualized treatment plans considering age, comorbidities, and tolerability are paramount. Further research is warranted to elucidate optimal BP targets and pharmacotherapeutic strategies tailored to the elderly.
40410113
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis.
2025 Jul
Journal of the Formosan Medical Association = Taiwan yi zhi
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "*Hypertension/drug therapy/complications", "Aged", "*Atrial Fibrillation/drug therapy", "*Heart Failure/drug therapy", "*Antihypertensive Agents/therapeutic use", "*Atherosclerosis/drug therapy", "Blood Pressure/drug effects", "*Aortic Valve Stenosis/drug therapy", "Practice Guidelines ...
4
2
chunk_000085
review
0.4741
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
Evidence is emerging to indicate that atrial fibrillation (AF) is independently associated with an increased risk of sudden cardiac death (SCD). This association has been consistently observed in specific patient subgroups such as patients with myocardial infarction (MI), heart failure, and hypertension, and importantly, in the general population.
25262841
Atrial fibrillation and its association with sudden cardiac death.
2014
Circulation journal : official journal of the Japanese Circulation Society
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "*Atrial Fibrillation/mortality/pathology/physiopathology/therapy", "Death, Sudden, Cardiac/*epidemiology", "Defibrillators, Implantable", "Humans", "Hypertension/mortality/pathology/physiopathology/therapy", "Myocardial Infarction/mortality/pathology/physiopathology/therapy", "Risk Factors", "Tachyca...
0
2
chunk_000086
review
0.4009
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.1895, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
Data from studies of implantable cardioverter-defibrillator recipients suggest that the rapid and irregular rhythm of AF and the short-long-short cycles that are highly prevalent in AF increase susceptibility to ventricular tachycardia and ventricular fibrillation.
25262841
Atrial fibrillation and its association with sudden cardiac death.
2014
Circulation journal : official journal of the Japanese Circulation Society
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "*Atrial Fibrillation/mortality/pathology/physiopathology/therapy", "Death, Sudden, Cardiac/*epidemiology", "Defibrillators, Implantable", "Humans", "Hypertension/mortality/pathology/physiopathology/therapy", "Myocardial Infarction/mortality/pathology/physiopathology/therapy", "Risk Factors", "Tachyca...
1
1
chunk_000087
review
0.4009
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.1895, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
An alternative explanation for the association between AF and SCD includes confounding or mediation by shared risk factors such as coronary artery disease and heart failure. Possible risk factors for SCD in patients with AF include black race, left ventricular hypertrophy, history of MI, and diabetes.
25262841
Atrial fibrillation and its association with sudden cardiac death.
2014
Circulation journal : official journal of the Japanese Circulation Society
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "*Atrial Fibrillation/mortality/pathology/physiopathology/therapy", "Death, Sudden, Cardiac/*epidemiology", "Defibrillators, Implantable", "Humans", "Hypertension/mortality/pathology/physiopathology/therapy", "Myocardial Infarction/mortality/pathology/physiopathology/therapy", "Risk Factors", "Tachyca...
2
2
chunk_000088
review
0.4009
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.1895, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
Additional research is needed to confirm the inherent proarrhythmic nature of AF, identify patients' characteristics or clinical conditions that potentiate SCD risk, and define effective SCD prevention strategies for patients with AF.
25262841
Atrial fibrillation and its association with sudden cardiac death.
2014
Circulation journal : official journal of the Japanese Circulation Society
Cardiovascular
[ "Journal Article", "Research Support, N.I.H., Extramural", "Review" ]
[ "*Atrial Fibrillation/mortality/pathology/physiopathology/therapy", "Death, Sudden, Cardiac/*epidemiology", "Defibrillators, Implantable", "Humans", "Hypertension/mortality/pathology/physiopathology/therapy", "Myocardial Infarction/mortality/pathology/physiopathology/therapy", "Risk Factors", "Tachyca...
3
1
chunk_000089
review
0.4009
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.1895, "sample_size_score": 0.2, "journal_impact_score": 0.82 }
There have been many recent advancements in cardiology research, with numerous studies published across the multiple subspecialties. Having screened more than 1200 articles published in 2024, we summarize 10 studies in this article that highlight key changes in this field.
40163883
Cardiology: What You May Have Missed in 2024.
2025 May
Annals of internal medicine
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "Atrial Fibrillation/therapy", "Anticoagulants/therapeutic use", "Heart Failure/therapy/drug therapy", "*Cardiology/trends", "Catheter Ablation", "Myocardial Infarction/therapy", "Aortic Valve Stenosis/therapy", "Adrenergic beta-Antagonists/therapeutic use" ]
0
2
chunk_000090
review
0.5416
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.85 }
Starting with atrial fibrillation (AF), we note articles that examine which patients benefit most from catheter ablation, a procedure that is becoming increasingly common. We then examine new evidence regarding anticoagulation in device-detected AF and in patients with AF and coronary disease.
40163883
Cardiology: What You May Have Missed in 2024.
2025 May
Annals of internal medicine
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "Atrial Fibrillation/therapy", "Anticoagulants/therapeutic use", "Heart Failure/therapy/drug therapy", "*Cardiology/trends", "Catheter Ablation", "Myocardial Infarction/therapy", "Aortic Valve Stenosis/therapy", "Adrenergic beta-Antagonists/therapeutic use" ]
1
2
chunk_000091
review
0.5416
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.85 }
In patients with severe aortic stenosis, the timing of valve intervention in relation to development of symptoms was a hot topic and is addressed here. There have also been developments in treatment of heart failure with preserved ejection fraction, including research into medications such as finerenone and tirzepatide.
40163883
Cardiology: What You May Have Missed in 2024.
2025 May
Annals of internal medicine
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "Atrial Fibrillation/therapy", "Anticoagulants/therapeutic use", "Heart Failure/therapy/drug therapy", "*Cardiology/trends", "Catheter Ablation", "Myocardial Infarction/therapy", "Aortic Valve Stenosis/therapy", "Adrenergic beta-Antagonists/therapeutic use" ]
2
2
chunk_000092
review
0.5416
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.85 }
Certain studies attempt to challenge our current medical practices, including routine use of beta-blockers after myocardial infarction (MI) and holding of renin-angiotensin system inhibitors before noncardiac surgery.
40163883
Cardiology: What You May Have Missed in 2024.
2025 May
Annals of internal medicine
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "Atrial Fibrillation/therapy", "Anticoagulants/therapeutic use", "Heart Failure/therapy/drug therapy", "*Cardiology/trends", "Catheter Ablation", "Myocardial Infarction/therapy", "Aortic Valve Stenosis/therapy", "Adrenergic beta-Antagonists/therapeutic use" ]
3
1
chunk_000093
review
0.5416
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.85 }
Finally, the role of invasive treatment strategies for older adults with non-ST-segment elevation MI has also been addressed.
40163883
Cardiology: What You May Have Missed in 2024.
2025 May
Annals of internal medicine
Cardiovascular
[ "Journal Article", "Review" ]
[ "Humans", "Atrial Fibrillation/therapy", "Anticoagulants/therapeutic use", "Heart Failure/therapy/drug therapy", "*Cardiology/trends", "Catheter Ablation", "Myocardial Infarction/therapy", "Aortic Valve Stenosis/therapy", "Adrenergic beta-Antagonists/therapeutic use" ]
4
1
chunk_000094
review
0.5416
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.8706, "sample_size_score": 0.2, "journal_impact_score": 0.85 }
Adrenomedullin (AM) is a vasodilative peptide with various physiological functions, including the maintenance of vascular tone and endothelial barrier function. AM levels are markedly increased during severe inflammation, such as that associated with sepsis; thus, AM is expected to be a useful clinical marker and therapeutic agent for inflammation.
34992239
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
2022 Mar
Hypertension research : official journal of the Japanese Society of Hypertension
Cardiovascular
[ "Journal Article", "Review" ]
[ "Adrenomedullin/therapeutic use", "*Cardiovascular Diseases/drug therapy", "*Heart Failure/drug therapy", "Humans", "*Hypertension, Pulmonary", "*Myocardial Infarction/drug therapy" ]
0
2
chunk_000095
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
However, as the increase in AM levels in cardiovascular diseases (CVDs) is relatively low compared to that in infectious diseases, the value of AM as a marker of CVDs seems to be less important. Limitations pertaining to the administrative route and short half-life of AM in the bloodstream (<30 min) restrict the therapeutic applications of AM for CVDs.
34992239
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
2022 Mar
Hypertension research : official journal of the Japanese Society of Hypertension
Cardiovascular
[ "Journal Article", "Review" ]
[ "Adrenomedullin/therapeutic use", "*Cardiovascular Diseases/drug therapy", "*Heart Failure/drug therapy", "Humans", "*Hypertension, Pulmonary", "*Myocardial Infarction/drug therapy" ]
1
2
chunk_000096
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
In early human studies, various applications of AM for CVDs were attempted, including for heart failure, myocardial infarction, pulmonary hypertension, and peripheral artery disease; however, none achieved success.
34992239
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
2022 Mar
Hypertension research : official journal of the Japanese Society of Hypertension
Cardiovascular
[ "Journal Article", "Review" ]
[ "Adrenomedullin/therapeutic use", "*Cardiovascular Diseases/drug therapy", "*Heart Failure/drug therapy", "Humans", "*Hypertension, Pulmonary", "*Myocardial Infarction/drug therapy" ]
2
1
chunk_000097
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We have developed AM as a therapeutic agent for inflammatory bowel disease in which the vasodilatory effect of AM is minimized. A clinical trial evaluating this AM formulation for acute cerebral infarction is ongoing.
34992239
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
2022 Mar
Hypertension research : official journal of the Japanese Society of Hypertension
Cardiovascular
[ "Journal Article", "Review" ]
[ "Adrenomedullin/therapeutic use", "*Cardiovascular Diseases/drug therapy", "*Heart Failure/drug therapy", "Humans", "*Hypertension, Pulmonary", "*Myocardial Infarction/drug therapy" ]
3
2
chunk_000098
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
We have also developed AM derivatives that exhibit a longer half-life and less vasodilative activity. These AM derivatives can be administered by subcutaneous injection at long-term intervals. Accordingly, these derivatives will reduce the inconvenience in use compared to that for native AM and expand the possible applications of AM for treating CVDs.
34992239
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
2022 Mar
Hypertension research : official journal of the Japanese Society of Hypertension
Cardiovascular
[ "Journal Article", "Review" ]
[ "Adrenomedullin/therapeutic use", "*Cardiovascular Diseases/drug therapy", "*Heart Failure/drug therapy", "Humans", "*Hypertension, Pulmonary", "*Myocardial Infarction/drug therapy" ]
4
3
chunk_000099
review
0.4149
{ "study_type_score": 0.5, "citation_score": 0.3, "recency_score": 0.5744, "sample_size_score": 0.2, "journal_impact_score": 0.4 }
End of preview.